275 related articles for article (PubMed ID: 31134668)
1. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Automated Insulin Management Features of the MiniMed
Zhong A; Choudhary P; McMahon C; Agrawal P; Welsh JB; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2016 Oct; 18(10):657-663. PubMed ID: 27672710
[TBL] [Abstract][Full Text] [Related]
4. Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
De Valk HW; Lablanche S; Bosi E; Choudhary P; Silva JD; Castaneda J; Vorrink L; De Portu S; Cohen O
Diabetes Technol Ther; 2018 Nov; 20(11):758-766. PubMed ID: 30325656
[TBL] [Abstract][Full Text] [Related]
5. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomised controlled home trial to evaluate the Suspend before low function.
Abraham MB; Nicholas JA; Ly TT; Roby HC; Paramalingam N; Fairchild J; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
BMJ Open; 2016 Apr; 6(4):e011589. PubMed ID: 27084290
[TBL] [Abstract][Full Text] [Related]
7. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes.
Abraham MB; Nicholas JA; Smith GJ; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
Diabetes Care; 2018 Feb; 41(2):303-310. PubMed ID: 29191844
[TBL] [Abstract][Full Text] [Related]
9. Pumps that predict and manage low blood glucose are superior to pumps with stand-alone CGM for reducing hypoglycaemia in type 1 diabetes patients in a real-world setting.
Telliam C; Thivolet C
Diabetes Metab; 2021 May; 47(3):101168. PubMed ID: 32497708
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of MiniMed 640G with SmartGuard® System for prevention of hypoglycemia in pediatric patients with type 1 diabetes mellitus.
Villafuerte Quispe B; Martín Frías M; Roldán Martín MB; Yelmo Valverde R; Álvarez Gómez MÁ; Barrio Castellanos R
Endocrinol Diabetes Nutr; 2017 Apr; 64(4):198-203. PubMed ID: 28417874
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
[TBL] [Abstract][Full Text] [Related]
12. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Automated Insulin Suspension and Glucose Responses with the Predictive Low-Glucose Management System.
Abraham MB; Smith GJ; Nicholas JA; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
Diabetes Technol Ther; 2019 Jan; 21(1):28-34. PubMed ID: 30585769
[TBL] [Abstract][Full Text] [Related]
14. The Incremental Benefits of the Predictive Low-Glucose Suspend Function Compared to the Low-Glucose Suspend Function as Automation Against Hypoglycemia in Sensor-Augmented Pump Therapy.
Beato-Víbora PI; Gil-Poch E; Galán-Bueno L; Lázaro-Martín L; Arroyo-Díez FJ
J Diabetes Sci Technol; 2018 Nov; 12(6):1241-1243. PubMed ID: 30058373
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend.
Gómez AM; Henao DC; Imitola A; Muñoz OM; Sepúlveda MAR; Kattah L; Guerrero JS; Morros E; Llano JP; Jaramillo MG; León-Vargas F
Endocrinol Diabetes Nutr (Engl Ed); 2018 Oct; 65(8):451-457. PubMed ID: 29914817
[TBL] [Abstract][Full Text] [Related]
16. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
[TBL] [Abstract][Full Text] [Related]
17. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
[TBL] [Abstract][Full Text] [Related]
19. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
[TBL] [Abstract][Full Text] [Related]
20. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
